JP2012523417A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012523417A5 JP2012523417A5 JP2012504760A JP2012504760A JP2012523417A5 JP 2012523417 A5 JP2012523417 A5 JP 2012523417A5 JP 2012504760 A JP2012504760 A JP 2012504760A JP 2012504760 A JP2012504760 A JP 2012504760A JP 2012523417 A5 JP2012523417 A5 JP 2012523417A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- lcvr
- hcvr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 33
- 102100015284 DKK1 Human genes 0.000 claims 9
- 101700029587 DKK1 Proteins 0.000 claims 9
- 102000004965 antibodies Human genes 0.000 claims 9
- 108090001123 antibodies Proteins 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 4
- 210000000988 Bone and Bones Anatomy 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims 2
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000035876 healing Effects 0.000 claims 2
- 201000009251 multiple myeloma Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000000295 complement Effects 0.000 claims 1
Claims (15)
- 軽鎖可変領域(LCVR)および重鎖可変領域(HCVR)を含み、LCVRが相補的決定領域(CDR)LCDR1、LCDR2、およびLCDR3を含み、HCVRがCDR HCDR1、HCDR2、およびHCDR3を含み、LCDR1が配列番号5のアミノ酸配列を有し、LCDR2が配列番号47のアミノ酸配列を有し、LCDR3が配列番号49のアミノ酸配列を有し、HCDR1が配列番号1のアミノ酸配列を有し、HCDR2が配列番号2のアミノ酸配列を有し、HCDR3が配列番号44のアミノ酸配列を有する
ヒト遺伝子操作DKK−1抗体。 - LCVRが配列番号52のアミノ酸配列を含み、HCVRが配列番号51のアミノ酸配列を含む、請求項1記載のヒト遺伝子操作DKK−1抗体。
- LCDR2が配列番号8のアミノ酸配列を有し、LCDR3が配列番号7のアミノ酸配列を有し、HCDR3が配列番号4のアミノ酸配列を有する請求項1記載のヒト遺伝子操作DKK−1抗体。
- 該LCVRおよび該HCVRが、以下の(i)〜(iv):
(i)該LCVRが配列番号13のアミノ酸配列を含み、該HCVRが配列番号11のアミノ酸配列を含む;
(ii)該LCVRが配列番号14のアミノ酸配列を含み、該HCVRが配列番号12のアミノ酸配列を含む;
(iii)該LCVRが配列番号15のアミノ酸配列を含み、該HCVRが配列番号11のアミノ酸配列を含む;
(iv)該LCVRが配列番号16のアミノ酸配列を含み、該HCVRが配列番号11のアミノ酸配列を含む;
からなる群より選択されるアミノ酸配列を含む、請求項2に記載のヒト遺伝子操作DKK−1抗体。 - 該LCVRが配列番号14のアミノ酸配列を含み、該HCVRが配列番号12のアミノ酸配列を含む、請求項4に記載のヒト遺伝子操作DKK−1抗体。
- 以下の(a)〜(d):
(a)該重鎖が配列番号17のアミノ酸配列を含み、該軽鎖が配列番号19のアミノ酸配列を含む、
(b)該重鎖が配列番号18のアミノ酸配列を含み、該軽鎖が配列番号20のアミノ酸配列を含む、
(c)該重鎖が配列番号17のアミノ酸配列を含み、該軽鎖が配列番号21のアミノ酸配列を含む、および
(d)該重鎖が配列番号17のアミノ酸配列を含み、該軽鎖が配列番号22のアミノ酸配列を含む、
からなる群より選択される該重鎖および該軽鎖のアミノ酸配列を含む請求項4に記載のヒト遺伝子操作DKK−1抗体。 - 各軽鎖が配列番号20のアミノ酸配列を含む2本の軽鎖、および、各重鎖が配列番号18のアミノ酸配列を含む2本の重鎖、を含むヒト遺伝子操作DKK−1抗体。
- 請求項1または6に記載のヒト遺伝子操作DKK−1抗体、および、医薬的に許容される担体、希釈剤、または賦形剤を含む、医薬組成物。
- 骨の治癒の治療に用いるための、請求項8に記載の組成物。
- 癌の治療に用いるための、請求項8に記載の組成物。
- 該癌が、多発性骨髄腫、乳癌、および非小細胞肺癌からなる群より選択される、請求項10に記載の組成物。
- 請求項7に記載のヒト遺伝子操作DKK−1抗体、および医薬的に許容される担体、希釈剤、または賦形剤を含む、医薬組成物。
- 骨の治癒の治療に用いるための、請求項12に記載の組成物。
- 癌の治療に用いるための、請求項12に記載の組成物。
- 該癌が、多発性骨髄腫、乳癌、および非小細胞肺癌からなる群より選択される、請求項14に記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16841109P | 2009-04-10 | 2009-04-10 | |
US61/168,411 | 2009-04-10 | ||
PCT/US2010/030039 WO2010117980A1 (en) | 2009-04-10 | 2010-04-06 | Dkk-1 antibodies |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2012523417A JP2012523417A (ja) | 2012-10-04 |
JP2012523417A5 true JP2012523417A5 (ja) | 2013-05-16 |
JP5759977B2 JP5759977B2 (ja) | 2015-08-05 |
Family
ID=42199718
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012504760A Active JP5759977B2 (ja) | 2009-04-10 | 2010-04-06 | Dkk−1抗体 |
Country Status (30)
Country | Link |
---|---|
US (1) | US8148498B2 (ja) |
EP (3) | EP2930184B1 (ja) |
JP (1) | JP5759977B2 (ja) |
KR (3) | KR101461362B1 (ja) |
CN (1) | CN102388065B (ja) |
AR (1) | AR075989A1 (ja) |
AU (1) | AU2010234611B2 (ja) |
BR (1) | BRPI1014157B1 (ja) |
CA (1) | CA2758252C (ja) |
CY (3) | CY1119399T1 (ja) |
DK (3) | DK2930184T3 (ja) |
EA (1) | EA021401B1 (ja) |
ES (3) | ES2728911T3 (ja) |
HR (3) | HRP20171400T1 (ja) |
HU (3) | HUE034625T2 (ja) |
IL (1) | IL214845A (ja) |
LT (3) | LT2417158T (ja) |
ME (2) | ME03378B (ja) |
MX (1) | MX2011010707A (ja) |
NZ (1) | NZ595011A (ja) |
PL (3) | PL2930184T3 (ja) |
PT (3) | PT2417158T (ja) |
RS (3) | RS62214B1 (ja) |
SG (1) | SG175244A1 (ja) |
SI (3) | SI2930184T1 (ja) |
TR (1) | TR201907261T4 (ja) |
TW (1) | TWI546079B (ja) |
UA (1) | UA103916C2 (ja) |
WO (1) | WO2010117980A1 (ja) |
ZA (1) | ZA201107256B (ja) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010131185A1 (en) | 2009-05-12 | 2010-11-18 | Pfizer Inc. | Blocking anti-dkk-1 antibodies and their uses |
ES2780398T3 (es) | 2012-12-10 | 2020-08-25 | Biogen Ma Inc | Anticuerpo anti-antígeno 2 de células dendríticas sanguíneas y uso de los mismos |
BR112017020610A2 (pt) | 2015-05-18 | 2018-07-17 | Lilly Co Eli | Compostos de anticorpo biespecífico anti-dkk-1- anti-rankl |
CN108137702B (zh) * | 2015-08-28 | 2023-01-06 | 艾利妥 | 抗siglec-7抗体及其使用方法 |
SI3370768T1 (sl) * | 2015-11-03 | 2022-04-29 | Janssen Biotech, Inc. | Protitelesa, ki se specifično vežejo na PD-1, in njihove uporabe |
RU2019115946A (ru) * | 2016-10-26 | 2020-11-27 | Лип Терапьютикс, Инк. | Применение бета-катенина в качестве биомаркера для лечения форм рака с помощью антитела к dkk-1 |
CN113395978A (zh) * | 2018-07-11 | 2021-09-14 | 动量制药公司 | 与靶向CTLA-4的工程化Fc-抗原结合结构域构建体有关的组合物和方法 |
CN112121147B (zh) * | 2019-06-24 | 2023-07-04 | 中国人民解放军海军特色医学中心 | 多肽在治疗或预防骨髓瘤药物中的应用、多肽、核酸、药物及重组表达载体 |
CA3151228A1 (en) | 2019-09-19 | 2021-03-25 | Leap Therapeutics, Inc. | Use of dkk-1 inhibitors for treating cancer |
JP2023502666A (ja) | 2019-11-22 | 2023-01-25 | リープ セラピューティクス,インコーポレイテッド | Dkk-1阻害剤を用いて癌を処置する方法 |
KR102494042B1 (ko) * | 2020-11-20 | 2023-02-07 | 주식회사 하울바이오 | 인간모유두세포의 성장을 촉진하는 항-dkk-1 항체 및 이의 용도 |
CN112592402B (zh) * | 2020-12-02 | 2022-04-26 | 杭州奕安济世生物药业有限公司 | 抗dkk2抗体、包含该抗dkk2抗体的组合物及其用途 |
EP4288098A1 (en) * | 2021-02-05 | 2023-12-13 | Omeros Corporation | Biomarker for assessing the risk of developing acute covid-19 and post-acute covid-19 |
WO2023039249A1 (en) | 2021-09-10 | 2023-03-16 | Leap Therapeutics, Inc. | Combination therapy |
WO2024015463A1 (en) | 2022-07-12 | 2024-01-18 | Leap Therapeutics, Inc. | Combination therapy |
CN116589590B (zh) * | 2023-03-21 | 2024-03-26 | 浙江大学 | 一种特异性抗异菌脲的单克隆抗体及其重组表达质粒 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
ATE353964T1 (de) | 1997-04-16 | 2007-03-15 | Millennium Pharm Inc | Crsp-proteine (cystein-reiche, sekretierte proteine), die dafür kodierenden nukleinsäuren und ihre verwendungen |
DE19747418C1 (de) | 1997-10-27 | 1999-07-15 | Deutsches Krebsforsch | Inhibitor-Protein des wnt-Signalwegs |
US7446181B2 (en) * | 1998-01-15 | 2008-11-04 | Millennium Pharmaceuticals, Inc. | Antibodies that bind human Dickkopf-1 proteins |
PT1490386E (pt) | 1998-03-10 | 2008-11-24 | Genentech Inc | Novos polipéptidos e ácidos nucleicos que os codificam |
WO2001057190A2 (en) | 2000-02-03 | 2001-08-09 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
EP2280030A3 (en) | 2001-04-10 | 2011-06-15 | Agensys, Inc. | Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers |
IL158750A0 (en) | 2001-05-17 | 2004-05-12 | Genome Therapeutics Corp | Reagents and methods for modulating dkk-mediated interactions |
US20040038860A1 (en) * | 2002-05-17 | 2004-02-26 | Allen Kristina M. | Reagents and methods for modulating dkk-mediated interactions |
WO2003053215A2 (en) | 2001-11-07 | 2003-07-03 | The Board Of Trustees Of The University Of Arkansas | Diagnosis prognosis and identification of potential therapeutic targets of multiple myeloma based on gene expression profiling |
US7371736B2 (en) * | 2001-11-07 | 2008-05-13 | The Board Of Trustees Of The University Of Arkansas | Gene expression profiling based identification of DKK1 as a potential therapeutic targets for controlling bone loss |
US7308364B2 (en) * | 2001-11-07 | 2007-12-11 | The University Of Arkansas For Medical Sciences | Diagnosis of multiple myeloma on gene expression profiling |
US7642238B2 (en) * | 2002-12-05 | 2010-01-05 | Shaughnessy John D | Molecular determinants of myeloma bone disease and uses thereof |
US20050084494A1 (en) * | 2003-05-21 | 2005-04-21 | Darwin Prockop | Inhibitors of Dkk-1 |
WO2005028678A2 (en) | 2003-06-06 | 2005-03-31 | Wyeth | Methods and materials for identifying agents which modulate bone remodeling and agents identified thereby |
EP2336177A1 (en) | 2004-08-04 | 2011-06-22 | Amgen, Inc | Antibodies to DKK-1 |
AR060017A1 (es) | 2006-01-13 | 2008-05-21 | Novartis Ag | Composiciones y metodos de uso para anticuerpos de dickkopf -1 |
CN101641373B (zh) * | 2007-02-08 | 2015-02-11 | 默沙东公司 | Dkk-1的特异性抗体 |
WO2010129752A1 (en) * | 2009-05-07 | 2010-11-11 | Novartis Ag | Compositions and methods of use for binding molecules to dickkopf-1 or dickkopf-4 or both |
-
2010
- 2010-03-29 AR ARP100101019A patent/AR075989A1/es active IP Right Grant
- 2010-04-02 TW TW099110438A patent/TWI546079B/zh active
- 2010-04-06 JP JP2012504760A patent/JP5759977B2/ja active Active
- 2010-04-06 SG SG2011075579A patent/SG175244A1/en unknown
- 2010-04-06 WO PCT/US2010/030039 patent/WO2010117980A1/en active Application Filing
- 2010-04-06 HU HUE10712681A patent/HUE034625T2/en unknown
- 2010-04-06 TR TR2019/07261T patent/TR201907261T4/tr unknown
- 2010-04-06 AU AU2010234611A patent/AU2010234611B2/en active Active
- 2010-04-06 PT PT107126815T patent/PT2417158T/pt unknown
- 2010-04-06 HU HUE15159780A patent/HUE043904T2/hu unknown
- 2010-04-06 DK DK15159780.4T patent/DK2930184T3/da active
- 2010-04-06 CA CA2758252A patent/CA2758252C/en active Active
- 2010-04-06 EP EP15159780.4A patent/EP2930184B1/en active Active
- 2010-04-06 KR KR1020147005305A patent/KR101461362B1/ko active IP Right Grant
- 2010-04-06 DK DK10712681.5T patent/DK2417158T4/da active
- 2010-04-06 SI SI201031877T patent/SI2930184T1/sl unknown
- 2010-04-06 EP EP19156509.2A patent/EP3514173B8/en active Active
- 2010-04-06 ES ES15159780T patent/ES2728911T3/es active Active
- 2010-04-06 UA UAA201111272A patent/UA103916C2/ru unknown
- 2010-04-06 BR BRPI1014157-0A patent/BRPI1014157B1/pt active IP Right Grant
- 2010-04-06 EP EP10712681.5A patent/EP2417158B9/en active Active
- 2010-04-06 DK DK19156509.2T patent/DK3514173T3/da active
- 2010-04-06 ME MEP-2019-98A patent/ME03378B/me unknown
- 2010-04-06 LT LTEP10712681.5T patent/LT2417158T/lt unknown
- 2010-04-06 EA EA201171237A patent/EA021401B1/ru not_active IP Right Cessation
- 2010-04-06 ES ES10712681.5T patent/ES2644244T3/es active Active
- 2010-04-06 SI SI201031526T patent/SI2417158T1/sl unknown
- 2010-04-06 LT LTEP19156509.2T patent/LT3514173T/lt unknown
- 2010-04-06 RS RS20210998A patent/RS62214B1/sr unknown
- 2010-04-06 KR KR1020147018130A patent/KR20140090273A/ko not_active Application Discontinuation
- 2010-04-06 MX MX2011010707A patent/MX2011010707A/es active IP Right Grant
- 2010-04-06 ES ES19156509T patent/ES2887176T3/es active Active
- 2010-04-06 RS RS20170959A patent/RS56505B1/sr unknown
- 2010-04-06 PT PT191565092T patent/PT3514173T/pt unknown
- 2010-04-06 US US12/754,637 patent/US8148498B2/en active Active
- 2010-04-06 ME MEP-2017-212A patent/ME02798B/me unknown
- 2010-04-06 CN CN201080015994.4A patent/CN102388065B/zh active Active
- 2010-04-06 PT PT15159780T patent/PT2930184T/pt unknown
- 2010-04-06 NZ NZ595011A patent/NZ595011A/xx unknown
- 2010-04-06 RS RS20190470A patent/RS58612B1/sr unknown
- 2010-04-06 PL PL15159780T patent/PL2930184T3/pl unknown
- 2010-04-06 HU HUE19156509A patent/HUE055376T2/hu unknown
- 2010-04-06 PL PL10712681T patent/PL2417158T3/pl unknown
- 2010-04-06 LT LTEP15159780.4T patent/LT2930184T/lt unknown
- 2010-04-06 SI SI201032080T patent/SI3514173T1/sl unknown
- 2010-04-06 KR KR1020117023571A patent/KR20110124364A/ko not_active Application Discontinuation
- 2010-04-06 PL PL19156509T patent/PL3514173T3/pl unknown
-
2011
- 2011-08-25 IL IL214845A patent/IL214845A/en active IP Right Grant
- 2011-10-04 ZA ZA2011/07256A patent/ZA201107256B/en unknown
-
2017
- 2017-09-15 HR HRP20171400TT patent/HRP20171400T1/hr unknown
- 2017-09-29 CY CY20171101022T patent/CY1119399T1/el unknown
-
2019
- 2019-04-03 HR HRP20190643TT patent/HRP20190643T1/hr unknown
- 2019-05-17 CY CY20191100531T patent/CY1121637T1/el unknown
-
2021
- 2021-08-06 CY CY20211100700T patent/CY1124412T1/el unknown
- 2021-08-20 HR HRP20211343TT patent/HRP20211343T1/hr unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2012523417A5 (ja) | ||
HRP20171992T1 (hr) | Protutijela protiv cgrp | |
JP2013542194A5 (ja) | ||
HRP20191678T1 (hr) | Pd-1 protutijelo, njegov fragment koji se veže na antigen, i njegova medicinska primjena | |
JP2015514110A5 (ja) | ||
SI3042917T1 (en) | PROTITELES AGAINST N3PGL AMILOID BETA PEPTID AND THEIR APPLICATION | |
JP2020500538A5 (ja) | ||
RU2019112029A (ru) | Применение комбинации антитела к pd-1 и ингибитора vegfr в изготовлении лекарственного средства для лечения злокачественных новообразований | |
NZ610294A (en) | Human antibodies to human tnf-like ligand 1a (tl1a) | |
RU2018105846A (ru) | Комбинация антагониста pd-1 с ингибитором egfr | |
NZ600768A (en) | Human antibodies to human angiopoietin-like protein 4 | |
JP2013529183A5 (ja) | ||
NZ602892A (en) | Antibodies that bind human cd27 and uses thereof | |
JP2013542191A5 (ja) | ||
MX2019007848A (es) | Anticuerpos anti-pd-1 y usos de los mismos. | |
NZ603972A (en) | Anti-fgfr2 antibodies | |
PE20130226A1 (es) | Anticuerpos hacia gdf8 humano | |
JP2015535828A5 (ja) | ||
TN2012000416A1 (en) | Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases | |
NZ610734A (en) | Human antibodies to the glucagon receptor | |
NZ628943A (en) | Human antibodies to clostridium difficile toxins | |
NZ705848A (en) | Anti-cd38 antibodies | |
EA032189B9 (ru) | Изолированные человеческие моноклональные антитела против ингибитора пути тканевого фактора (tfpi) и фармацевтическая композиция, содержащая их | |
RU2015110981A (ru) | Комбинации и их применение | |
NZ590863A (en) | Anti-hepcidin-25 selective antibodies and uses thereof |